Enveda Biosciences
- 25/04/2023
- Series B
- $51,000,000
At Enveda, we are systematically translating molecules found in medicinal plants into new drugs for challenging diseases. Our platform harnesses nature's complexity with the help of cutting-edge advancements in knowledge graphs, machine learning, and metabolomics.
- Industry Biotechnology Research
- Website https://www.envedabio.com/
- LinkedIn https://www.linkedin.com/company/envedabio/
Related People
Viswa ColluruFounder
I believe in the revolutionary power of technology, the monumental potential of human ingenuity, and radical empiricism as our primary tool to engineer around the complexity of natural systems. I’m working with a dream-team of co-believers to distill these elements into practice at Enveda Biosciences, where we’re building a platform to map the molecular patterns underlying humanity’s use of medicinal plants to systematically discover high-value transformative therapeutics.
Prior to Enveda, I was a key early team member at Recursion, where I led the company's foray outside rare disease as an innovation scientist, articulated value propositions and delivered pitches around those platforms to multiple top 10 pharma partners as a discovery product manager, and switched hats a second time to set the commercial vision for internal drug candidates across multiple therapeutic areas (see https://medium.com/recursion-pharmaceuticals/celebrating-the-departure-of-an-outstanding-employee-65db2455fd1f). While in graduate school, I pioneered three technologies to improve cancer therapies by leveraging the patient's own immune system.
I am passionate about creating meaningful, lasting impact geared towards maximizing the well-being of as many people on this planet as possible.